Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. [electronic resource]
Producer: 20200417ISSN:- 1946-6242
- Aged
- Animals
- Antibodies, Monoclonal, Humanized -- pharmacology
- Benzodiazepinones -- pharmacology
- Carcinoma, Neuroendocrine -- drug therapy
- Cell Line, Tumor
- Gene Expression Regulation, Neoplastic -- drug effects
- Genetic Heterogeneity
- Humans
- Immunoconjugates -- pharmacology
- Intracellular Signaling Peptides and Proteins -- genetics
- Male
- Membrane Proteins -- genetics
- Mice
- Molecular Targeted Therapy
- Neoplastic Cells, Circulating -- metabolism
- Prostatic Neoplasms -- drug therapy
- Prostatic Neoplasms, Castration-Resistant -- drug therapy
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.